BID and melanoma: Accordingly, the association of ABT-737 with specific Mcl-1 targeting (with siRNA or maritoclax) or with the Bcl-2-family inhibitor obatoclax, along with Noxa overexpression, has produced interesting results in terms of reduction in melanoma cell viability and colony formation and of apoptosis induction; these effects were associated with increased Bim expression, Bid and Bax activation, cleavage of PARP and of caspase-9, -8, -3 (148,156,166–168).